drugset / Trial / NCT05153096
Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This trial is an open-label, multicenter, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The aim of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NBL-015 in patients with advanced solid tumors.
Timeline
- Start
- 2022-04
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBL-015 | Unknown | 1 mg/kg | Intravenous |
| Subject | NBL-015 | Unknown | 3 mg/kg | Intravenous |
| Subject | NBL-015 | Unknown | 10 mg/kg | Intravenous |
| Subject | NBL-015 | Unknown | 20 mg/kg | Intravenous |
| Subject | NBL-015 | Unknown | 30 mg/kg | Intravenous |